Publications

Validation analysis of a composite real-world mortality endpoint for patients with cancer in the US →

Zhang, Q, Gossai, A, Monroe, S, Nussbaum, NC, Parrinello, CM

May 2021

Manuscript

Health Services Research

Flatiron-authored

Treatment sequence after first-line nivolumab plus ipilimumab or sunitinib monotherapy in patients with metastatic renal cell carcinoma using real-world data →

Geynisman, DM, Faccone, J, Zhang, Y, Ejzykowicz, F, Hamilton, M, Le, TK, Huo, S

February 2021

Abstract

ASCO GU Symposium

Real-world treatment patterns and sequencing for metastatic renal cell carcinoma: results from the Flatiron database →

George, S, Faccone, J, Huo, S, Zhang, Y, Stwalley, B, Hamilton, M, Le, TK, Ejzykowicz, F

February 2021

Abstract

ASCO GU Symposium

Deriving International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk categories using oncology electronic health records →

Mathur, R, Barata, P, Tan, K, Pini, M, Magee, K, Baxi, SS

November 2020

Abstract

EU ISPOR

Flatiron-authored

Uptake of first-line immune checkpoint inhibitors among medically frail patients with advanced solid malignancies →

Parikh, RB, Cohen, RB, Min, EJ, Wileyto, EP, Riaz, F, Gross, CP, Long, Q, Mamtani, R

May 2020

Abstract

ASCO Annual Meeting

Affordable Care Act Medicaid expansion impact on racial disparities in time to cancer treatment →

Adamson B, Cohen AB, Estevez M, Magee K, Williams E, Gross CP, Meropol NJ, Davidoff AJ

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

Organ dysfunction and clinical outcomes in patients treated with immune checkpoint inhibitors →

Liu Q, Sharon E, Zineh I, Xie D, Baxi SS, Liu C, Zhi J, Torres AZ, Gossai A, Sridhara R, Booth B, Blumenthal GM, Huang S-M, Khozin S

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

Temporally integrated framework for treatment intervals (TIFTI): A framework for extracting drug intervals from longitudinal clinic notes →

Agrawal, M, Adams, G, Nussbaum, NC, Birnbaum, B

December 2018

Abstract

Machine Learning for Health (ML4H) Workshop

Flatiron-authored

Disparities in the use of programmed death 1 immune checkpoint inhibitors →

O’Connor, JM, Seidl-Rathkopf, K, Torres, AZ, You, P, Carson, KR, Ross, JS, Gross, CP

July 2018

Manuscript

The Oncologist

Flatiron-authored

Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials →

O’Connor J, Fessele K, Steiner J, Seidl-Rathkopf K, Carson K, Nussbaum N, Yin E, Adelson K, Presley C, Chiang A, Ross J, Abernethy AP, Gross C

May 2018

Manuscript

JAMA Oncology

Flatiron-authored

Adoption of Immunotherapy into Real World Practice: Insights from the Use of Checkpoint Inhibitors →

O’Connor J, Seidl-Rathkopf K, You P, Nussbaum N, Torres AZ, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy AP, Gross C

June 2017

Abstract

ASCO Annual Meeting

Flatiron-authored

Racial Disparities in the Use of Programmed Death-1 Checkpoint Inhibitors →

O’Connor J, Seidl-Rathkopf K, You P, Nussbaum N, Torres AZ, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy AP, Gross C

June 2017

Abstract

ASCO Annual Meeting

Flatiron-authored

Chemotherapy Use Near End of Life (EOL): Measuring Real World Benchmarks →

Kraut J, Gippetti J, Peterson D, Agarwala V, Revol C, Fessele K, Abernethy AP

March 2017

Abstract

ASCO Quality Care Symposium

Flatiron-authored